Trial · NCT00278421
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00278421, Phase 3, Completed, German High-Grade Non-Hodgkin's Lymphoma Study Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma. Trials, record NCT00278421. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00278421
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- NCT number
- NCT00278421
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 592 participants, actual
- Lead sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- First posted
- 2006-01-18
- Last updated
- 2021-03-11
- Other registries' IDs
- eudract:2005-005217-38
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to treatment failure (TTF) measured from day 1 of course 1 of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) therapy up to 3 years on study with life-long follow-up | through study completion | |
| Secondary | Complete response (CR) rate duration until first relapse | through study completion | |
| Secondary | Progression rate during treatment | through study completion | |
| Secondary | Survival | through study completion | |
| Secondary | Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored) | through study completion | |
| Secondary | Disease-free survival measured from day 1 of course 1 of CHOP therapy | through study completion | |
| Secondary | Safety (adverse events, serious adverse events) assessed at 3 months after treatment | through study completion |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 31868632 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00278421
GET https://conductscience.org/api/trials/v1/NCT00278421/registered